These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27921141)

  • 41. Urinary pH and stone formation.
    Wagner CA; Mohebbi N
    J Nephrol; 2010; 23 Suppl 16():S165-9. PubMed ID: 21170875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of patients with uric acid stones.
    Heilberg IP
    Urolithiasis; 2016 Feb; 44(1):57-63. PubMed ID: 26645868
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes.
    Bell DS
    Diabetes Obes Metab; 2012 Apr; 14(4):299-303. PubMed ID: 21992452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors increasing the risk for stone formation in adult patients with cystic fibrosis.
    Terribile M; Capuano M; Cangiano G; Carnovale V; Ferrara P; Petrarulo M; Marangella M
    Nephrol Dial Transplant; 2006 Jul; 21(7):1870-5. PubMed ID: 16595587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimization of urolithiasis treatment and diagnosis in the Turkestan region.
    Fathi R
    J Med Life; 2022 Mar; 15(3):344-349. PubMed ID: 35449989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Obesity and metabolic stone disease.
    Wollin DA; Skolarikos A; Preminger GM
    Curr Opin Urol; 2017 Sep; 27(5):422-427. PubMed ID: 28650866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biochemical profile of idiopathic uric acid nephrolithiasis.
    Pak CY; Sakhaee K; Peterson RD; Poindexter JR; Frawley WH
    Kidney Int; 2001 Aug; 60(2):757-61. PubMed ID: 11473659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An update and practical guide to renal stone management.
    Johri N; Cooper B; Robertson W; Choong S; Rickards D; Unwin R
    Nephron Clin Pract; 2010; 116(3):c159-71. PubMed ID: 20606476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 24-h uric acid excretion and the risk of kidney stones.
    Curhan GC; Taylor EN
    Kidney Int; 2008 Feb; 73(4):489-96. PubMed ID: 18059457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Urinary alkalization for the treatment of uric acid nephrolithiasis.
    Cicerello E; Merlo F; Maccatrozzo L
    Arch Ital Urol Androl; 2010 Sep; 82(3):145-8. PubMed ID: 21121431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is there a risk for kidney stone formation in cystic fibrosis?
    Böhles H; Michalk D
    Helv Paediatr Acta; 1982 Jun; 37(3):267-72. PubMed ID: 7118558
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oxypurines, protein, glucose and the functional state of blood vasculature are markers of renal calcium stone-forming processes? Observations in men with idiopathic recurrent calcium urolithiasis.
    Manoharan M; Schwille PO
    Clin Chem Lab Med; 2002 Mar; 40(3):266-77. PubMed ID: 12005217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan.
    Kohjimoto Y; Sasaki Y; Iguchi M; Matsumura N; Inagaki T; Hara I
    Am J Kidney Dis; 2013 Jun; 61(6):923-9. PubMed ID: 23433467
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The growing prevalence of kidney stones and opportunities for prevention.
    Richman K; O'Bell J; Pareek G
    R I Med J (2013); 2014 Dec; 97(12):31-4. PubMed ID: 25463625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones.
    Alvarez Arroyo MV; Traba ML; Rapado A
    Urol Int; 1992; 48(3):342-6. PubMed ID: 1589930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic Syndrome and Kidney Stone Disease: A Systematic Review of Literature.
    Wong Y; Cook P; Roderick P; Somani BK
    J Endourol; 2016 Mar; 30(3):246-53. PubMed ID: 26576717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Essential arterial hypertension and stone disease.
    Borghi L; Meschi T; Guerra A; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Jun; 55(6):2397-406. PubMed ID: 10354288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of renal function on urinary mineral excretion and stone composition.
    Kadlec AO; Greco KA; Fridirici ZC; Gerber D; Turk TM
    Urology; 2011 Oct; 78(4):744-7. PubMed ID: 21664652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease.
    Trinchieri A; Lizzano R; Castelnuovo C; Zanetti G; Pisani E
    Arch Ital Urol Androl; 2002 Jun; 74(2):61-4. PubMed ID: 12161938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.